Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward C Stack

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Nature Genetics|June 4, 2013
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Cancer Medicine|May 22, 2014
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladderElizabeth A Guancial, Lillian Werner, Joaquim Bellmunt, et al.
Neuro-Oncology|April 5, 2013
Phase 2 study of dose-intense temozolomide in recurrent glioblastomaAndrew D Norden, Glenn J Lesser, Jan Drappatz, et al.
Science (New York, N.Y.)|December 15, 2012
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independentKexin Xu, Zhenhua Jeremy Wu, Anna C Groner, et al.
Cancer Immunology Research|February 23, 2018
Quantitative Analysis of Immune Infiltrates in Primary MelanomaRobyn D Gartrell, Douglas K Marks, Thomas D Hart, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 28, 2012
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisAndreas Pettersson, Rebecca E Graff, Scott R Bauer, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 26, 2012
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesisChiara Grisanzio, Lillian Werner, David Takeda, et al.
Cancer Discovery|March 15, 2014
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanibNikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
Oncoimmunology|November 10, 2022
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibodyJessica D Weaver, Edward C Stack, Joshua A Buggé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2014
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinomaMarkus Riester, Lillian Werner, Joaquim Bellmunt, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Nature Genetics|June 4, 2013
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Cancer Medicine|May 22, 2014
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladderElizabeth A Guancial, Lillian Werner, Joaquim Bellmunt, et al.
Neuro-Oncology|April 5, 2013
Phase 2 study of dose-intense temozolomide in recurrent glioblastomaAndrew D Norden, Glenn J Lesser, Jan Drappatz, et al.
Science (New York, N.Y.)|December 15, 2012
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independentKexin Xu, Zhenhua Jeremy Wu, Anna C Groner, et al.
Cancer Immunology Research|February 23, 2018
Quantitative Analysis of Immune Infiltrates in Primary MelanomaRobyn D Gartrell, Douglas K Marks, Thomas D Hart, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 28, 2012
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisAndreas Pettersson, Rebecca E Graff, Scott R Bauer, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 26, 2012
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesisChiara Grisanzio, Lillian Werner, David Takeda, et al.
Cancer Discovery|March 15, 2014
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanibNikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
Oncoimmunology|November 10, 2022
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibodyJessica D Weaver, Edward C Stack, Joshua A Buggé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2014
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinomaMarkus Riester, Lillian Werner, Joaquim Bellmunt, et al.
Pageof 5